Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2206 | Norepinephrine |
| Norepinephrine is a peripheral vasoconstrictor by acting on alpha-adrenergic receptors, it can up-regulate the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Norepinephrine can stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Noradrenergic system may play a significant role in modulating the development of ischemic neuronal damage. | |
| BCN2208 | Ergocalciferol |
| Ergocalciferol (Vitamin D2) is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 mM. Ergocalciferol can delay the development of secondary hyperparathyroidism in children with CKD2-3. Ergocalciferol can cause HL-60 apoptosis via a modulation of mitochondria involving ROS production, GSH depletion, caspase activation, and Fas induction, on the basis of anticancer activity of ergocalciferol, it may be feasible to develop chemopreventive agents from edible mushrooms or hop. Ergocalciferol can prevent glucocorticoid-induced bone loss, but even increase lumbar spine and femoral neck bone mineral densities (BMD) in postmenopausal women commencing glucocorticoid therapy, it also is safe and effective in reducing the risk of a fracture in elderly patients with AD. | |
| BCN2269 | Gomisin G |
| Gomisin G is a drug candidate for treatment of cardiovascular disease, and it is a good substrate of CYP2C9, and can be easily affected by the inhibitors of CYP2C9. Gomisin G exhibits anti-tumor activities, it exhibits potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 microgram/mL and 300, respectively. | |
| BCN2270 | Gomisin J |
| Gomisin J is a good substrate of cytochrome P450 3A4(CYP3A4), it has vasodilatory, anti-inflammatory, anti-diabetes, anti-oxidant, and anti-cancer effects, it also has preventive effects on angiotensin II-induced hypertension via an increased nitric oxide bioavailability. Gomisin J has potential benefits in treating nonalcoholic fatty liver disease, it can suppress lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecule. Halogenated gomisin J is a potent inhibitor of the cytopathic effects of human immunodeficiency virus type 1 (HIV-1) on MT-4 human T cells (50% effective dose, 0.1 to 0.5 microM). | |
| BCN2271 | Gomisin N |
| Gomisin N has anti-oxdiant, anti-inflammatory, anti-cancer and anti-hepatitis activities; it produces beneficial sedative and hypnotic bioactivity, which may be mediated by the modification of the serotonergic and GABAergic system. Gomisin N can enhance TNF-α-induced apoptosis by suppressing of NF-κB and EGFR signaling pathways, and potentiate TRAIL-induced apoptosis through ROS-mediated up-regulation of death receptors 4 and 5. | |
